GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cosmo Bio Co Ltd (TSE:3386) » Definitions » Debt-to-Revenue

Cosmo Bio Co (TSE:3386) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Cosmo Bio Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cosmo Bio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円20 Mil. Cosmo Bio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0 Mil. Cosmo Bio Co's annualized Revenue for the quarter that ended in Dec. 2023 was 円9,852 Mil. Cosmo Bio Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


Cosmo Bio Co Debt-to-Revenue Historical Data

The historical data trend for Cosmo Bio Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Bio Co Debt-to-Revenue Chart

Cosmo Bio Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cosmo Bio Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cosmo Bio Co's Debt-to-Revenue

For the Diagnostics & Research subindustry, Cosmo Bio Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Bio Co's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cosmo Bio Co's Debt-to-Revenue falls into.



Cosmo Bio Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cosmo Bio Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Cosmo Bio Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Cosmo Bio Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cosmo Bio Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Bio Co (TSE:3386) Business Description

Traded in Other Exchanges
N/A
Address
2-20, Toyo-Ekimae Building, Toyo 2-Chome, Koto-ku, Tokyo, JPN, 135-0016
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes purchase of reagents, instruments, clinical test drugs for research on life science and domestic sales.

Cosmo Bio Co (TSE:3386) Headlines

No Headlines